Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions

ObjectiveAmivantamab plus chemotherapy has been proved to be an efficient treatment strategy for non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions. The aim of this study was to conduct the cost-effectiveness analysis of amivantamab-chemotherapy compar...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Ping Yue, Mengwei Zhang, Yuanying Feng, Yuan Gao, Chao Sun, Peng Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	amivantamab chemotherapy cost-effectiveness analysis non-small-cell lung cancer papillon
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1368804/full